Reaction: Crizotinib to 1 product

Reaction
Crizotinib
DB08865
    PF-06260182
    DBMET03537
    Reaction type
    oxidation
    Direction
    Major circulating metabolite?
    No
    Spontaneous?
    No
    Activity
    active
    References
    1. FDA Clinical Pharmacology and Biopharmaceutics Review: XALKORI (crizotinib) capsules for oral use [Link]
    Comments
    Not Available
    Enzymes
    Not Available